Founded as the first manufacturer of the market in its category in 2002 by Prof. Dr. Haluk Ataoğlu, Matriks Biotek® produces ELISA test kits and monoclonal antibodies for research and better understanding of the diseases. The Matriks Biotek® “Shikari®” ELISA kits and anti-drug antibody ELISA kits can be efficiently used, for monitoring serum trough levels and the presence of anti-drug antibodies respectively, during therapy and offers the scientist a tool for taking decisions on possible preventive measures.
There is a continuous R&D on going on at the company. Major fields are inflammation, infectious diseases, Obesity, type II diabetes and cardiovascular diseases, where we try to understand the pathophysiology, develop targets for diagnosis and treatment.
Our products are exported to 35 countries mainly to North America, Europe, Israel, India, Japan, China and Australia. We have 20 distributors all over the world.
Contact
Gazi Üniversitesi Gölbaşı Yerleşkesi Teknoplaza Binası (B Blok Zemin Kat BZ17) 06830
Gölbaşı, ANKARA, TÜRKİYE
Phone: +90 (312) 485 42 94
Fax: +90 (312) 485 11 87
E-Mail: info@matriksbiotek.com
Haluk Ataoglu, academic turned founder of Matriks Biotek®, talks about his aspirations for his company and the Turkish R&D landscape as well as how to penetrate the global pharmaceutical market…
In the world’s 18th largest market, recent pricing struggles have pushed some companies to revaluate their investment approach. Multinational organizations are complying with localization policies but are divided between having…
Arven Pharmaceuticals is the Turkish R&D-based company behind the first biosimilar drug developed and manufactured from cell to final product in the country, and the first patented and produced dry…
Ercin Kugu, CSL Behring’s general manager for Turkey and Israel, highlights the rare disease company’s footprint in Turkey, explains the different regulatory framework in the country for plasma products, and…
Boehringer Ingelheim (BI), the largest private pharma company in the world, has become the latest Big Pharma player to commit to Turkish localization after announcing a contract manufacturing partnership with…
After being present in the Turkish market for more than 28 years, MSD seems confident that it will be able to seize upcoming opportunities due to the country’s high prevalence…
Over a decade ago, GE Healthcare selected Turkey as an international operational base for its Eastern and Africa Growth Markets (EAGM) and 84 countries are managed from Turkey today. Nael…
Dogan Taskent, board member of the Swiss Chamber of Commerce in Turkey, highlights Turkey’s successful response to the COVID-19 pandemic, how the local R&D ecosystem collaborated, often for free, to…
Amgen, the American biotech giant, established a direct presence in Turkey in 2010 by acquiring a local generics manufacturer for US 700 million. Its general manager in the country, Güldem…
Few Turkish companies are experiencing such a transformational moment as GEN. Just in 2021, the Ankara-based organization made its public debut at the Istanbul Stock Exchange and signed an exclusive…
The president of the Turkish Health Institutes (TUSEB), Dr Erhan Akdoğan, provides a behind-the-scenes look at the development process of Turkovac, the country’s first homegrown COVID-19 vaccine which is currently…
Ersin Erfa, CEO of Centurion, a Turkish manufacturer, discusses the company’s high ambitions, R&D capabilities, and their work on a COVID-19 treatment currently in phase II clinical trials. Erfa explains…
Best known as the company that launched the world’s first “antibody biosimilar,” Celltrion is looking to continue its growth as a global biopharmaceutical company. Its general manager for Turkey, SeokHoon…
See our Cookie Privacy Policy Here
